دورية أكاديمية
Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.
| العنوان: | Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. |
|---|---|
| المؤلفون: | González de Requena D; Department of Infectious Diseases, University of Turin, Turin, Italy., Calcagno A, Bonora S, Ladetto L, D'Avolio A, Sciandra M, Siccardi M, Bargiacchi O, Sinicco A, Di Perri G |
| المصدر: | AIDS (London, England) [AIDS] 2006 Oct 03; Vol. 20 (15), pp. 1977-9. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 8710219 Publication Model: Print Cited Medium: Print ISSN: 0269-9370 (Print) Linking ISSN: 02699370 NLM ISO Abbreviation: AIDS Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1998- : London, England : Lippincott Williams & Wilkins Original Publication: London : Gower Academic Journals, c1987- |
| مواضيع طبية MeSH: | Anti-HIV Agents/*pharmacokinetics , Peptide Fragments/*pharmacokinetics , Pyridines/*pharmacokinetics , Pyrones/*pharmacokinetics , Ritonavir/*pharmacokinetics, Anti-HIV Agents/therapeutic use ; Antiretroviral Therapy, Highly Active ; Cohort Studies ; Drug Interactions ; Enfuvirtide ; Female ; HIV Envelope Protein gp41/therapeutic use ; HIV Fusion Inhibitors/pharmacokinetics ; HIV Fusion Inhibitors/therapeutic use ; HIV Infections/drug therapy ; HIV Protease Inhibitors/pharmacokinetics ; HIV Protease Inhibitors/therapeutic use ; HIV-1 ; Half-Life ; Humans ; Male ; Peptide Fragments/therapeutic use ; Pyridines/therapeutic use ; Pyrones/therapeutic use ; Ritonavir/therapeutic use ; Sulfonamides |
| مستخلص: | Fifty-five patients placed on tipranavir/ritonavir 500/200 mg twice a day (27 with enfuvirtide and 28 without) underwent tipranavir and ritonavir plasma concentration measurements by high-pressure liquid chromatography. Markedly higher tipranavir and ritonavir trough concentrations were observed in enfuvirtide recipients. The modelling of sparse plasma samples using a first order absorption and elimination monocompartmental model without time lag predicted higher tipranavir elimination half-life and volume of distribution in enfuvirtide takers. This unexpected drug-drug interaction warrants further investigation. |
| المشرفين على المادة: | 0 (Anti-HIV Agents) 0 (HIV Envelope Protein gp41) 0 (HIV Fusion Inhibitors) 0 (HIV Protease Inhibitors) 0 (Peptide Fragments) 0 (Pyridines) 0 (Pyrones) 0 (Sulfonamides) 19OWO1T3ZE (Enfuvirtide) O3J8G9O825 (Ritonavir) ZZT404XD09 (tipranavir) |
| تواريخ الأحداث: | Date Created: 20060922 Date Completed: 20071024 Latest Revision: 20201209 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1097/01.aids.0000247121.19951.fa |
| PMID: | 16988521 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0269-9370 |
|---|---|
| DOI: | 10.1097/01.aids.0000247121.19951.fa |